Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling

Neuro-Oncology

Volumn 18, Issue 4, 2016, Pages 518-527

  Cockle, Julia V ^a   Rajani, Karishma ^b   Zaidi, Shane ^b,c   Kottke, Timothy ^b   Thompson, Jill ^b   Diaz, Rosa Maria ^b   Shim, Kevin ^b   Peterson, Tim ^d   Parney, Ian F ^d   Short, Susan ^a   Selby, Peter ^a   Ilett, Elizabeth ^a   Melcher, Alan ^a   Vile, Richard ^a,b,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MAYO GRADUATE SCHOOL   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d MAYO CLINIC   (United States)

Author keywords

cancer immunotherapy; checkpoint inhibitor; glioma; oncolytic virus; vesicular stomatitis virus

Indexed keywords

CD11B ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA PLUS MYC PROTEIN PLUS TRANSCRIPTION FACTOR SOX10 ONCOLYTIC VIRUS; INTERLEUKIN 17; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PD1; ONCOLYTIC VIRUS; TYROSINASE RELATED PROTEIN 1; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR MICROENVIRONMENT; VESICULOVIRUS; ANIMAL; BRAIN NEOPLASMS; C3H MOUSE; C57BL MOUSE; CELL CYCLE; CELL CYCLE CHECKPOINT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL CYCLE; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; TUMOR CELLS, CULTURED; VESICULOVIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84966474725     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov173     Document Type: Article

References (21)

1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237-251.
2. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559-567.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med. 2010;363(5):411-422.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med. 2010;363(8):711-723.
5. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014;20(22):5620-5629.
6. Kottke T, Errington F, Pulido J, et al. Broad antigenic coverage induced by viral cDNA library-based vaccination cures established tumors. Nature Med. 2011;2011:854-859.
7. Pulido J, Kottke T, Thompson J, et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol. 2012;30(4):337-343.
8. Alonso-Camino V, Rajani K, Kottke T, et al. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther. 2014;22:1936-1948.
9. Boisgerault N, Kottke T, Pulido J, et al. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther. 2013;21(8):1507-1516.
10. Zaidi S, Blanchard M, Shim K, et al. Mutated BRAF emerges as a major effector of recurrence in a murine melanoma model after treatment with immunomodulatory agents. Mol Ther. 2015; 23(5):845-856.
11. Kottke T, Sanchez-Perez L, Diaz RM, et al. Induction of hsp70-mediated, Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res. 2007;67:11970-11979.
12. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic anti-tumor immunity. Hum Gene Ther. 1996;7:1771-1779.
13. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol. 2002;76(2):895-904.
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
15. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015;33C:23-35.
16. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107(2):359-364.
17. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer. 2013;108(8):1560-1565.
18. Engeland CE, Grossardt C, Veinalde R, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22(11):1949-1959.
19. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12(7 Pt 1):2264-2271.
20. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines. 2013;12(10):1155-1172.
21. Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015; doi: 10.1200/JCO.2014.58.3377. [Epub ahead of print].